title: [The place of Glitazones in the treatment of diabetes: after the PROactive study].
abstract: Thiazolidinediones (TZD) have recently been introduced as an oral hypoglycaemic agent. A vast amount of data indicates that TZD also exhibit beneficial cardiovascular effects. This article reports on the results from the large PROactive study. After 3 years of pioglitazone treatment a reduction in the frequency of death, non-fatal myocardial infarction and cerebral infarction was demonstrated in type 2 diabetic subjects. However, there were side effects in terms of cardial insufficiency and edema. Though this study provides some clear cut answers, it also raises a lot of questions.
authors.affiliation: Arhus Universitetshospital, Medicinsk Endokrinologisk Afdeling M. ole.schmitz@ki.au.dk
authors.forename: Ole E
authors.initials: OE
authors.lastname: Schmitz
authors.forename: Birgitte
authors.initials: B
authors.lastname: Brock
authors.forename: Jørgen
authors.initials: J
authors.lastname: Rungby
authors.forename: Sten
authors.initials: S
authors.lastname: Madsbad
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000077205:Pioglitazone; D011446:Prospective Studies; D012107:Research Design; D012307:Risk Factors; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone